Authors: Carmen Gasca-Salas, MD, MSc, PhD, Medical Director, Medpace
Key Takeaways in Neurodegenerative Research from AD/PD 2026
Recently, the Medpace neuroscience team attended the AD/PD (Alzheimer’s & Parkinson’s Disease) 2026 Conference. The conference was especially compelling this year, with a wide range of breakthrough data and emerging therapeutic strategies presented across neurodegenerative disease research. It was particularly exciting to see the continued acceleration of innovation in disease – biomarker development, early intervention strategies, and modifying approaches.
A few key takeaways stood out, including advancements in earlier and more precise diagnostic tools, growing momentum in targeted therapies aimed at slowing disease progression and confirmed long-term benefits that better bridge preclinical findings with clinical outcomes. Continue reading to get the full AD/PD 2026 comprehensive recap capturing key insights from our neuroscience experts.
Key AD/PD Conference Takeaways:
Precision Biomarkers Transforming Detection
One of the main takeaways was the reinforcement that plasma pTau217 can detect preclinical and early Alzheimer´s disease (AD) pathology with high precision. It may replace PET/CSF in some contexts and could help monitor disease progression.
The advancement of high-precision single assays and multiplex protein platforms for the early detection and differential diagnosis of AD, Parkinson’s disease (PD) and other neurodegenerative disorders was also highlighted.
Advances in α-synuclein PET tracers (allowing the visualization of α-synuclein pathology in the living brain) tested in PD, Multiple System Atrophy and Dementia with Lewy Bodies (DLB) were also reported.
There was also a specific focus on digital biomarkers such as speech patterns, smartphone typing dynamics and gait for early detection of neurodegenerative disorders.
Evolving Approaches to Alzheimer’s Disease
Long-term data was presented for approved monoclonal antibody that specifically binds to amyloid beta aggregates for AD, confirming high treatment persistence, long-term benefit and manageable safety in clinical practice.
A novel monoclonal antibody strategy to clear amyloid plaques, with increased blood brain barrier penetrance, is being investigated.
Beyond anti-amyloid therapies, there was also increasing emphasis focus on other biological pathways like neuroinflammation, autophagy, and tau pathology.
Expanding the Parkinson’s Pipeline
The potential to slow motor progression in early-stage PD targeting aggregated α-synuclein was highlighted, showing sustained reduction in clinical decline compared to external controls.
The conference also highlighted early-stage studies in PD such as the inhibition of the NLRP3 inflammasome activity or those aiming to restore lysosomal function mainly through the activation of the glucocerebrosidase (GCase) enzyme.
Lastly, Cell Therapies autologous stem-cell-derived dopaminergic transplants of PD patients were shown to be safe, well tolerated, and showed signs of motor improvement in initial study phases.
An Industry Leader in Neurodegenerative Clinical Development
Accelerate the execution of your neurodegenerative disease study by partnering with a global CRO that not only understands the unique challenges of neurodegenerative diseases but also possesses the necessary experience to help you overcome them. As a scientifically-driven CRO, Medpace brings together a dedicated team of neuroscience experts who combine scientific leadership with operational excellence to help accelerate your neurodegenerative disease compound to approval.
Unable to connect with our experts at AD/PD? We welcome the opportunity to discuss your upcoming clinical development plans. Contact our neuroscience experts today.
